Pliant Therapeutics Stock

pliantrx.comHealthcareFounded: 2016Funding to Date: $187MM

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.

Register for Details

For more details on financing and valuation for Pliant Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Pliant Therapeutics.

Register Today

Team

Management Team

Bernard Coulie MD
Chief Executive Officer, President & Board Member
Hans Hull JD
Chief Business Officer
Dean Sheppard MD
Scientific Founder and Scientific Advisor, Translational Medicine
Barbara Howes
Chief Human Resources Officer
Éric Lefebvre MD
Chief Medical Officer
Hal Chapman MD
Scientific Founder and Scientific Advisor, Translational Medicine
Keith Cummings MD
Chief Financial Officer
Rik Derynck Ph.D
Scientific Co-Founder & Scientific Advisor of Biology
William DeGrado Ph.D
Scientific Founder

Board Members

John Curnutte MD
Neil Exter
Third Rock Ventures
Hoyoung Huh Ph.D
Kevin Raidy
Cowen Group
Suzanne Bruhn Ph.D
Craig Muir
Third Rock Ventures
Smital Shah
Charles Homcy MD
Third Rock Ventures

Other companies like Pliant Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$396.01MM
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B

News

Novartis has put up $80 million to land the global license to Pliant Therapeutics’ preclinical nonalcoholic steatohepatitis (NASH) asset and three additional candidates. The NASH drug, PLN-1474, is a small molecule inhibitor of integrin αVβ1 Pliant thinks can reduce the growth of fibrotic tissue in the liver.
Updated on: Jun 3, 2023